Inhibition of paracetamol glucuronidation by tyrosine kinase inhibitors
- 12 May 2011
- journal article
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 71 (6), 917-920
- https://doi.org/10.1111/j.1365-2125.2011.03911.x
Abstract
• Clinical cases reported that fatal acute liver failure occurred when paracetamol (acetaminophen) was co-administrated with some tyrosine kinase inhibitors (TKIs). The direct inhibition of UDP-glucuronosyltransferase activities has been identified as a mechanism of potentiation of paracetamol hepatotoxicity. However, the effects of TKIs on paracetamol glucuronidation are not known. • The TKIs, sorafenib, dasatinib and imatinib exhibited potent mixed inhibition against paracetamol glucuronidation in pooled human liver microsomes, implying a possible increase in paracetamol hepatotoxicity when they are co-administrated with paracetamol. AIMS We aimed to investigate the effects of tyrosine kinase inhibitors (TKIs) on paracetamol (acetaminophen) glucuronidation. The inhibition of nine small molecule TKIs on paracetamol glucuronidation was investigated in human liver microsomes (HLMs) and recombinant human UDP-glucuronosyltransferases (UGTs). Sorafenib, dasatinib and imatinib exhibited mixed inhibition against paracetamol glucuronidation in pooled HLMs, and potent inhibition in UGT1A9 and UGT2B15. Dasatinib and imatinib also inhibited UGT1A1-mediated paracetamol glucuronidation. Axitinib, erlotinib, gefitinib, lapatinib, nilotinib and vandetanib exhibited weak inhibition of paracetamol glucuronidation activity in HLMs. The inhibition of paracetamol glucuronidation by TKIs might be of particular concern when they are co-administered.This publication has 14 references indexed in Scilit:
- Comparison of the Drug-Drug Interactions Potential of Erlotinib and Gefitinib via Inhibition of UDP-GlucuronosyltransferasesDrug Metabolism and Disposition, 2009
- Fatal Liver Failure in a Patient on Acetaminophen Treated with Sunitinib Malate and LevothyroxineAnnals of Pharmacotherapy, 2009
- Results from an in vitro and a clinical/pharmacological phase I study with the combination irinotecan and sorafenibEuropean Journal of Cancer, 2007
- Kinetics of Acetaminophen Glucuronidation by UDP-Glucuronosyltransferases 1A1, 1A6, 1A9 and 2B15. Potential Implications in Acetaminophen−Induced HepatotoxicityChemical Research in Toxicology, 2006
- SELECTIVITY OF SUBSTRATE (TRIFLUOPERAZINE) AND INHIBITOR (AMITRIPTYLINE, ANDROSTERONE, CANRENOIC ACID, HECOGENIN, PHENYLBUTAZONE, QUINIDINE, QUININE, AND SULFINPYRAZONE) “PROBES” FOR HUMAN UDP-GLUCURONOSYLTRANSFERASESDrug Metabolism and Disposition, 2005
- Role of Tyrosine Kinase Inhibitors in Cancer TherapyThe Journal of pharmacology and experimental therapeutics, 2005
- Phenobarbital and Phenytoin Increased Acetaminophen Hepatotoxicity Due to Inhibition of UDP-Glucuronosyltransferases in Cultured Human HepatocytesToxicological Sciences, 2005
- Enhanced acetaminophen toxicity in rats with bilirubin glucuronyl transferase deficiencyHepatology, 1989
- Determinants of acetaminophen metabolism: Effect of inducers and inhibitors of drug metabolism on acetaminophen's metabolic pathwaysClinical Pharmacology & Therapeutics, 1984
- Kinetics and metabolism of paracetamol and phenacetin.British Journal of Clinical Pharmacology, 1980